Flavio Solca
About
Flavio Solca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Flavio Solca has authored 85 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 34 papers in Molecular Biology. Recurrent topics in Flavio Solca's work include Lung Cancer Treatments and Mutations (50 papers), HER2/EGFR in Cancer Research (32 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Flavio Solca is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), HER2/EGFR in Cancer Research (32 papers) and PI3K/AKT/mTOR signaling in cancer (10 papers). Flavio Solca collaborates with scholars based in Austria, Germany and United States. Flavio Solca's co-authors include Frank Himmelsbach, Anke Baum, Heidi Greulich, Takeshi Shimamura, Lucian R. Chirieac, Geoffrey I. Shapiro, Masaya Takahashi, Wolfgang J. Rettig, Matthew Meyerson and Kah Keng Wong and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Flavio Solca
84 papers receiving 3.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Flavio Solca Austria | 26 | 2.3k | 2.0k | 1.8k | 433 | 427 | 85 | 3.8k | ||
| Danan Li United States | 16 | 1.6k 0.7× | 1.0k 0.5× | 2.3k 1.3× | 236 0.5× | 193 0.5× | 21 | 3.2k | ||
| Ralf Brandt United States | 18 | 2.5k 1.1× | 1.1k 0.6× | 1.9k 1.0× | 165 0.4× | 632 1.5× | 27 | 4.0k | ||
| George N. Naumov United States | 22 | 2.3k 1.0× | 1.3k 0.7× | 1.9k 1.0× | 163 0.4× | 201 0.5× | 37 | 4.0k | ||
| Anke Baum Austria | 14 | 1.4k 0.6× | 978 0.5× | 1.6k 0.9× | 260 0.6× | 168 0.4× | 32 | 2.8k | ||
| Deric L. Wheeler United States | 37 | 2.5k 1.1× | 1.3k 0.6× | 2.5k 1.4× | 130 0.3× | 569 1.3× | 89 | 4.8k | ||
| Mario Mancino Italy | 19 | 1.2k 0.5× | 570 0.3× | 1.6k 0.9× | 159 0.4× | 286 0.7× | 34 | 2.8k | ||
| Diane Palmieri United States | 37 | 2.1k 0.9× | 1.9k 0.9× | 1.9k 1.0× | 110 0.3× | 358 0.8× | 52 | 4.6k | ||
| Terence O’Reilly Switzerland | 24 | 1.1k 0.5× | 668 0.3× | 2.0k 1.1× | 163 0.4× | 181 0.4× | 36 | 3.2k | ||
| Caterina Bianco United States | 41 | 2.4k 1.0× | 857 0.4× | 3.8k 2.1× | 167 0.4× | 436 1.0× | 76 | 5.4k | ||
| Dominic Fan United States | 37 | 2.0k 0.9× | 861 0.4× | 2.0k 1.1× | 114 0.3× | 284 0.7× | 72 | 4.1k |
Countries citing papers authored by Flavio Solca
Since
Specialization
Citations
This map shows the geographic impact of Flavio Solca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavio Solca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavio Solca more than expected).
Fields of papers citing papers by Flavio Solca
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Flavio Solca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavio Solca. The network helps show where Flavio Solca may publish in the future.
Co-authorship network of co-authors of Flavio Solca
This figure shows the co-authorship network connecting the top 25 collaborators of Flavio Solca. A scholar is included among the top collaborators of Flavio Solca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flavio Solca. Flavio Solca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Liu, Stephen V., Misako Nagasaka, Judith Atz, Flavio Solca, & Leonhard Müllauer. (2025). Oncogenic gene fusions in cancer: from biology to therapy. Signal Transduction and Targeted Therapy. 10(1). 111–111.
2.
Lee, You Won, Jii Bum Lee, Min Hee Hong, et al.. (2024). Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clinical Cancer Research. 30(8). 1582–1594.
3.
Geoerger, Birgit, Lynley V. Marshall, Karsten Nysom, et al.. (2023). Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. European Journal of Cancer. 188. 8–19.
4.
Tontsch-Grunt, Ulrike, Anke Baum, Hanny Musa, et al.. (2022). Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. British Journal of Cancer. 127(3). 577–586.
5.
Ruzicka, Regina, Laura L. Elo, Mark S. Johnson, et al.. (2022). An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Cancer Research Communications. 2(1). 10–27.
6.
Weyer-Czernilofsky, Ulrike, Marco H. Hofmann, Katrin Friedbichler, et al.. (2020). Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Molecular Cancer Therapeutics. 19(4). 1059–1069.
7.
Weinberg, Benjamin A., Daniel J. Renouf, Howard J. Lim, et al.. (2019). NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option. Annals of Oncology. 30. iv80–iv80.
8.
Ritter, Cathrin, Selma Ugurel, Lorenzo Cerroni, et al.. (2017). Non-reproducible sequence artifacts in FFPE tissue: an experience report. Journal of Cancer Research and Clinical Oncology. 143(7). 1199–1207.
9.
Ioannou, Nikolaos, Alan M. Seddon, Angus Dalgleish, et al.. (2016). Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International Journal of Oncology. 48(3). 908–918.
10.
Sini, Patrizia, Ulrich Gürtler, Stephan K. Zahn, et al.. (2016). Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases. Molecular Cancer Therapeutics. 15(10). 2388–2398.
11.
Canonici, Alexandra, Mattia Cremona, Bryan T. Hennessy, et al.. (2016). Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer. Annals of Oncology. 27. vi34–vi34.
12.
Goss, Glenwood, K.H. Lee, Enriqueta Felip, et al.. (2016). Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung. Annals of Oncology. 27. vi428–vi428.
13.
Li, W., Caicun Zhou, Enriqueta Felip, et al.. (2015). 443P Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes. Annals of Oncology. 26. ix125–ix125.
14.
Modjtahedi, Helmout, Byoung Chul Cho, Martin C. Michel, & Flavio Solca. (2014). A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg s Archives of Pharmacology. 387(6). 505–521.
15.
Kim, Sun Mi, Mi Ran Yun, Yun Hong, et al.. (2013). Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation. Molecular Cancer Therapeutics. 12(10). 2145–2156.
16.
Eberl, Markus, Stefan Klingler, Doris Mangelberger, et al.. (2012). Hedgehog‐EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour‐initiating pancreatic cancer cells. EMBO Molecular Medicine. 4(3). 218–233.
17.
Kim, Sun Mi, Oh-Joon Kwon, Yun Hong, et al.. (2012). Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation. Molecular Cancer Therapeutics. 11(10). 2254–2264.
18.
Solca, Flavio, Andreas Zoephel, Gerd Bader, et al.. (2012). Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. Journal of Pharmacology and Experimental Therapeutics. 343(2). 342–350.
19.
Shimamura, Takeshi, Heidi Greulich, Flavio Solca, & Kwok‐Kin Wong. (2007). C7-04: Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model. Journal of Thoracic Oncology. 2(8). S380–S380.
20.
Solca, Flavio, Yoram Salomon, & Alex N. Eberlé. (1991). Heterogeneity of the MSH Receptor Among B16 Murine Melanoma Subclones. Journal of Receptor Research. 11(1-4). 379–390.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Danan Li Breakdown of academic impact, for papers by Ralf Brandt Breakdown of academic impact, for papers by George N. Naumov Breakdown of academic impact, for papers by Anke Baum Breakdown of academic impact, for papers by Deric L. Wheeler Breakdown of academic impact, for papers by Mario Mancino Breakdown of academic impact, for papers by Diane Palmieri Breakdown of academic impact, for papers by Terence O’Reilly Breakdown of academic impact, for papers by Caterina Bianco Breakdown of academic impact, for papers by Dominic Fan